Nutriband (NASDAQ:NTRB) Shares Down 1% – Time to Sell?

Nutriband Inc. (NASDAQ:NTRB) fell 1% during trading on Thursday . The company traded as low as $3.03 and last traded at $3.06. 11,387 shares were traded during trading, a decline of 11% from the average daily volume of 12,846 shares. The stock had previously closed at $3.09.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Nutriband from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, June 17th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Nutriband has a consensus rating of “Reduce”.

Nutriband Stock Down 1.0%

The company has a fifty day moving average price of $3.50 and a 200 day moving average price of $3.99. The stock has a market cap of $37.20 million, a PE ratio of -1.19 and a beta of 1.93.

Nutriband (NASDAQ:NTRB) last issued its earnings results on Thursday, June 11th. The company reported ($0.10) earnings per share for the quarter. The company had revenue of $0.43 million for the quarter. Nutriband had a negative net margin of 448.25% and a negative return on equity of 112.64%.

Institutional Trading of Nutriband

An institutional investor recently bought a new stake in Nutriband stock. Cogent Private Wealth Inc. bought a new position in Nutriband Inc. (NASDAQ:NTRB) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 16,014 shares of the company’s stock, valued at approximately $73,000. Cogent Private Wealth Inc. owned about 0.13% of Nutriband as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 19.70% of the company’s stock.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.